b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">29244985</PMID>\n        <DateCompleted>\n            <Year>2018</Year>\n            <Month>07</Month>\n            <Day>19</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2018</Year>\n            <Month>11</Month>\n            <Day>13</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">2378-9506</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>3</Volume>\n                    <Issue>6</Issue>\n                    <PubDate>\n                        <Year>2017</Year>\n                        <Month>Dec</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Journal of global oncology</Title>\n                <ISOAbbreviation>J Glob Oncol</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Malignancy-Related Hypercalcemia in Advanced Solid Tumors: Survival Outcomes.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>728-733</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1200/JGO.2016.006890</ELocationID>\n            <Abstract>\n                <AbstractText>Purpose Malignancy-related hypercalcemia (MRH) is associated with a dismal prognosis. The widespread use of bisphosphonates (BPs), availability of more effective drugs in cancer treatment, and improvement in supportive care might have attenuated its impact. Patients and Methods To assess overall survival (OS) of patients with MRH in a contemporary setting, we conducted a retrospective analysis of 306 patients with solid cancer hospitalized for symptomatic hypercalcemia. A multivariable Cox proportional hazards regression model was performed to evaluate possible prognostic factors associated with MRH. Results All patients had serum ionized calcium &gt; 5.5 mg/dL or total Ca &gt; 10.5 mg/dL. Median age was 57 years, and the majority had squamous cell carcinoma (62%) and Eastern Cooperative Oncology Group performance status &gt; 1 (96%). Head and neck was the most frequent primary site (28%). Forty-five percent had no previous chemotherapy (CT), and subsequent CT was administered to 32%. Eighty-three percent received BP with no survival gain. Median OS was 40 (95% CI, 33 to 47) days. Patients with a performance status &gt; 2, altered mental status, C-reactive protein &gt; 30 mg/L, albumin &lt; 2.5 g/dL, or body mass index &lt; 18 kg/m<sup>2</sup> had significantly poorer survival in a univariable analysis, and longer OS was related to treatment-naive patients, subsequent CT, and breast primary site. In the multivariable analysis, subsequent CT led to a median OS improvement of 144 versus 25 days (hazard ratio, 0.24; 95% CI, 0.14 to 0.40; P &lt; .001). Conclusion In a contemporary setting, MRH remains a marker of poor prognosis. Patients treated with CT had better survival, which suggests that appropriate treatment of selected patients might alter the course of this syndrome.</AbstractText>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Ramos</LastName>\n                    <ForeName>Ricardo Emanuel de Oliveira</ForeName>\n                    <Initials>REO</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>All authors: Instituto do Cancer do Estado de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Perez Mak</LastName>\n                    <ForeName>Milena</ForeName>\n                    <Initials>M</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>All authors: Instituto do Cancer do Estado de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Alves</LastName>\n                    <ForeName>Michel Fabiano Silva</ForeName>\n                    <Initials>MFS</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>All authors: Instituto do Cancer do Estado de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Piotto</LastName>\n                    <ForeName>Gustavo Henrique Munhoz</ForeName>\n                    <Initials>GHM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>All authors: Instituto do Cancer do Estado de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Takahashi</LastName>\n                    <ForeName>Tiago Kenji</ForeName>\n                    <Initials>TK</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>All authors: Instituto do Cancer do Estado de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Gomes da Fonseca</LastName>\n                    <ForeName>Leonardo</ForeName>\n                    <Initials>L</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>All authors: Instituto do Cancer do Estado de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Silvino</LastName>\n                    <ForeName>Marina Cavalcanti Maroja</ForeName>\n                    <Initials>MCM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>All authors: Instituto do Cancer do Estado de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Hoff</LastName>\n                    <ForeName>Paulo Marcelo</ForeName>\n                    <Initials>PM</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>All authors: Instituto do Cancer do Estado de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>de Castro</LastName>\n                    <ForeName>Gilberto</ForeName>\n                    <Initials>G</Initials>\n                    <Suffix>Jr</Suffix>\n                    <AffiliationInfo>\n                        <Affiliation>All authors: Instituto do Cancer do Estado de S\xc3\xa3o Paulo, S\xc3\xa3o Paulo, Brazil.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2017</Year>\n                <Month>03</Month>\n                <Day>15</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>J Glob Oncol</MedlineTA>\n            <NlmUniqueID>101674751</NlmUniqueID>\n            <ISSNLinking>2378-9506</ISSNLinking>\n        </MedlineJournalInfo>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006934" MajorTopicYN="N">Hypercalcemia</DescriptorName>\n                <QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009369" MajorTopicYN="N">Neoplasms</DescriptorName>\n                <QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>\n                <QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D016019" MajorTopicYN="N">Survival Analysis</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName>\n            </MeshHeading>\n        </MeshHeadingList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2017</Year>\n                <Month>12</Month>\n                <Day>16</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2017</Year>\n                <Month>12</Month>\n                <Day>16</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2018</Year>\n                <Month>7</Month>\n                <Day>20</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">29244985</ArticleId>\n            <ArticleId IdType="doi">10.1200/JGO.2016.006890</ArticleId>\n            <ArticleId IdType="pmc">PMC5735968</ArticleId>\n        </ArticleIdList>\n        <ReferenceList>\n            <Reference>\n                <Citation>Support Care Cancer. 2013 May;21(5):1415-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">23229654</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Anticancer Res. 2009 May;29(5):1551-5</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19443365</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Adv Nurs. 2006 Mar;53(5):524-33</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16499673</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Endocrinol Metab. 2014 Sep;99(9):3144-52</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">24915117</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Oral Maxillofac Surg. 2003 Apr;32(2):174-80</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">12729778</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Curr Oncol. 2008 Jan;15(Suppl 1):S50-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">18231649</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Br J Cancer. 1995 Jul;72(1):206-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">7599053</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Cancer Res Clin Oncol. 1994;120(10):610-4</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">7929533</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Formos Med Assoc. 1990 Jul;89(7):548-53</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">1979596</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Support Care Cancer. 2009 Aug;17(8):1133-5</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">19290550</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Clin Lab. 2001;47(1-2):67-71</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11214225</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Oral Oncol. 2005 Oct;41(9):884-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">16043379</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Am J Hosp Palliat Care. 2011 Nov;28(7):515-7</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21724679</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Clin Oncol. 2001 Jan 15;19(2):558-67</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">11208851</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Cancer Res. 1986 Aug;46(8):4208-12</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">3731088</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Int J Oral Maxillofac Surg. 2011 Sep;40(9):938-42</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">21489752</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>N Engl J Med. 2005 Jan 27;352(4):373-9</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">15673803</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Urology. 1989 Mar;33(3):167-70</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">2521966</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Ann Intern Med. 1990 Apr 1;112(7):499-504</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">2138442</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Bull Cancer. 1995 Nov;82(11):975-80</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">8535025</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Support Care Cancer. 2008 Apr;16(4):387-92</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">17710443</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>J Urol. 1991 Feb;145(2):248-50</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">1988711</ArticleId>\n                </ArticleIdList>\n            </Reference>\n            <Reference>\n                <Citation>Acta Oncol. 1990;29(5):577-80</Citation>\n                <ArticleIdList>\n                    <ArticleId IdType="pubmed">2206569</ArticleId>\n                </ArticleIdList>\n            </Reference>\n        </ReferenceList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'